What Do Analysts Think About Amgen Inc. (AMGN)?

Group 1 - Amgen Inc. reported a 9% increase in total revenues to $9.2 billion for fiscal Q2 2025 compared to Q2 2024, with GAAP earnings per share rising 92% from $1.38 to $2.65, primarily due to higher revenues [1] - Analyst consensus for Amgen Inc. is a Moderate Buy, with a median price target of $276.39, indicating a potential upside of 12.16% from current levels [3] - Guggenheim maintained a Hold rating on Amgen Inc. with a price target of $288.00, while Raymond James initiated coverage with a Market Perform rating without a price target [2] Group 2 - Amgen Inc. is a biotechnology company focused on discovering, developing, manufacturing, and marketing human therapeutics, particularly for complex cancers with significant unmet needs [4]